Category: Biotechnology
-
Pediatric Exclusivity: How FDA Extends Patent Protection
Learn how pediatric exclusivity under Section 505A extends market protection for six months without changing patent terms, impacting drug lifecycle and generic entry.
-
Biosimilar Interchangeability: When Pharmacists Can Automatically Substitute Drugs
Learn when pharmacists can automatically substitute biosimilars. We explain FDA interchangeability, state laws, safety data, and how this impacts your medication costs.
-
Bioavailability vs Bioequivalence: What You Need to Know About Generics
Learn the difference between bioavailability and bioequivalence and how the FDA uses these concepts to ensure generic drugs are safe and effective.
-
Generic approval timelines: how long FDA reviews take in 2026
Explore current FDA generic drug approval timelines, ANDA processes, and GDUFA performance goals. Learn standard vs. priority review durations and tips for faster approval.
-
Reimbursement and Coding for Biosimilars: How Billing Works Under Medicare Part B
Biosimilars are billed differently than generics under Medicare Part B. Learn how coding, payment calculations, and the JZ modifier affect reimbursement-and why adoption remains low despite lower drug costs.
-
Fungal Biotechnology: Future Trends and Applications
Explore how fungi are reshaping biotechnology, from enzymes and biofuels to mycelium materials, and discover emerging tools, scaling challenges, and future trends.